Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 5/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587487 | 0.99 | MAPT (0.52) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL6585718 | 0.98 | MAPT (0.53) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL4000712 | 0.96 | MAPT (0.55) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL6556615 | 0.79 | MAPT (0.54) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL6585839 | 0.77 | PGR (0.62) | MAPTKDM4EALDH1A1PGRNR3C1 | |
| SCHEMBL6586035 | 0.76 | PGR (0.64) | MAPTKDM4EPGRNR3C1NR3C2 | |
| SCHEMBL3999113 | 0.75 | MEN1 (0.48) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL5077894 | 0.75 | MAPT (0.46) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL4184335 | 0.74 | MAPT (0.57) | MAPTKDM4EPOLBNPSR1ALDH1A1 | |
| SCHEMBL6554195 | 0.74 | NR3C1 (0.53) | MAPTKDM4EPOLBNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | claimed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | claimed |
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-0986545-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054159-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | MAPT 3996/4885KDM4E 4304/4885POLB 2946/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | MAPT 4055/4885KDM4E 4196/4885POLB 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.